
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio Inc is strategically positioned to capitalize on the development of groundbreaking therapies for rare CNS disorders, with an emphasis on early intervention which enhances the potential benefits of its lead product, PBFT02. The positive interim data from the June '25 upliFT-D study highlights the durability of Dose 1, exhibiting sustained increases in key biomarkers indicating a favorable response, which could lead to accelerated approval pathways. Moreover, the trial's concurrent enrollment of Cohort 3 aims to expedite progress, strengthening the company's prospects for successful outcomes in both the clinical and regulatory arenas.
Bears say
Passage Bio Inc. faces significant financial risks primarily due to potential clinical delays and safety concerns associated with its gene therapy programs PBGM01 and PBFT02, which could adversely affect market sentiment and lead to downward revisions in financial forecasts. The company is exposed to heightened regulatory risks and the challenges of developing sufficient manufacturing capacity, which could further constrain growth projections. Past experiences with gene therapy products underscore the unpredictability in safety and efficacy outcomes, creating a precarious environment for Passage Bio's future financial performance.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares